Retrieve available abstracts of 39 articles: HTML format
Single Articles
May 2025
HOLLIS RL, Herrington CS, Gourley C Response to letter RE: Somatic BRCA1/2 mutations are associated with a similar
survival advantage to their germline counterparts in tubo-ovarian high grade
serous carcinoma.
Eur J Cancer. 2025 May 5:115491. doi: 10.1016/j.ejca.2025.115491. PubMed
KARABUGA B, Baskurt K, Mammadzada N, Sutcuoglu O, et al Letter RE: Somatic BRCA1/2 mutations are associated with a similar survival
advantage to their germline counterparts in tubo-ovarian high-grade serous
carcinoma.
Eur J Cancer. 2025 May 4:115490. doi: 10.1016/j.ejca.2025.115490. PubMed
April 2025
FIORE M, Ljevar S, Raut CP, Personeni G, et al Impact and safety of pregnancy on desmoid fibromatosis management in the era of
active surveillance. An international multicenter retrospective observational
study.
Eur J Cancer. 2025;222:115474. PubMedAbstract available
STEVENTON L, Nicum S, Chambers P, Man K, et al Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following
poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent
ovarian cancer: A retrospective cohort study in England.
Eur J Cancer. 2025;222:115472. PubMedAbstract available
LIU W, Yang Y Letter re: The prognostic and clinical significance of substantial lymphovascular
space invasion in early-stage endometrial carcinoma.
Eur J Cancer. 2025 Apr 25:115446. doi: 10.1016/j.ejca.2025.115446. PubMed
ONAL C, Elmali A, Demirhan B, Guler OC, et al Letter comments on: "Induction chemotherapy followed by chemoradiation in locally
advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial".
Eur J Cancer. 2025 Apr 22:115448. doi: 10.1016/j.ejca.2025.115448. PubMed
EMINOWICZ G, Vaja S, Hackshaw A, McCormack M, et al Response to letter Re: Induction chemotherapy followed by chemoradiation in
locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE
trial.
Eur J Cancer. 2025 Apr 22:115449. doi: 10.1016/j.ejca.2025.115449. PubMed
BIGANZOLI G, Isnaldi E, Richard F, Marano G, et al Prognostic relation of body mass index on extended aromatase inhibition treatment
in postmenopausal patients with estrogen receptor positive breast cancer: A
retrospective analysis of the SOLE trial.
Eur J Cancer. 2025;222:115438. PubMedAbstract available
MAGATON IM, Blondeaux E, Hamy AS, Linn S, et al Assisted reproductive technology in young BRCA carriers with a pregnancy after
breast cancer: An international cohort study.
Eur J Cancer. 2025;222:115434. PubMedAbstract available
LEIBETSEDER A, Berghoff AS Response to letter commenting on "Association of pregnancy with tumour
progression in patients with glioma".
Eur J Cancer. 2025 Apr 9:115411. doi: 10.1016/j.ejca.2025.115411. PubMed
DANG C, Liu P, Yu X Letter Re: Association of pregnancy with tumour progression in patients with
glioma.
Eur J Cancer. 2025 Apr 4:115410. doi: 10.1016/j.ejca.2025.115410. PubMed
March 2025
MAENG CH, Han K, Hong JY, Park JH, et al Association between premature menopause and the risk of biliary tract cancer: A
nationwide cohort study.
Eur J Cancer. 2025;220:115387. PubMedAbstract available
EMINOWICZ G, Vaja S, Gallardo D, Kent C, et al Induction chemotherapy followed by chemoradiation in locally advanced cervical
cancer: Quality of life outcomes of the GCIG INTERLACE trial.
Eur J Cancer. 2025;220:115375. PubMedAbstract available
SIITONEN H, Joensuu J, Savolainen-Peltonen H, Gissler M, et al Update of the impact of menopausal hormone therapy on breast cancer risk.
Eur J Cancer. 2025;220:115340. PubMedAbstract available
CAPASSO I, Perrone E, Duranti S, Giannarelli D, et al Are all mismatch repair deficient endometrial cancers created equal? A large,
retrospective, tertiary center experience.
Eur J Cancer. 2025;220:115344. PubMedAbstract available
February 2025
VILLACAMPA G, Eminowicz G, Navarro V, Carita L, et al Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer:
A systematic review and network meta-analysis.
Eur J Cancer. 2025;220:115329. PubMedAbstract available
STEGER K, Fiegl H, Feroz B, Leitner K, et al Differences in immunogenicity of TP53-mutated cancers with low tumor mutational
burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast
cancer.
Eur J Cancer. 2025;219:115320. PubMedAbstract available
VERGOTE I, Copeland LJ, Van Gorp T, Laenen A, et al Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of
the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.
Eur J Cancer. 2025;219:115306. PubMedAbstract available
HASEGAWA K, Nishio S, Yamamoto K, Fujiwara H, et al Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical
cancer: Randomized trial.
Eur J Cancer. 2025;219:115304. PubMedAbstract available
HOLLIS RL, Churchman M, Grimes GR, Meynert AM, et al Somatic BRCA1/2 mutations are associated with a similar survival advantage to
their germline counterparts in tubo-ovarian high grade serous carcinoma.
Eur J Cancer. 2025;219:115299. PubMedAbstract available
January 2025
LI Z, Peng J, Zhang B, Zhao C, et al The prognostic and clinical significance of substantial lymphovascular space
invasion in early-stage endometrial carcinoma.
Eur J Cancer. 2025;218:115258. PubMedAbstract available
LEIBETSEDER A, Mair MJ, Serra AS, Spiro Z, et al Association of pregnancy with tumour progression in patients with glioma.
Eur J Cancer. 2025;218:115259. PubMedAbstract available
OAKNIN A, Monk BJ, de Melo AC, Kim HS, et al Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in
the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Eur J Cancer. 2025;216:115146. PubMedAbstract available
December 2024
MARME F, Krieghoff-Henning EI, Kiehl L, Wies C, et al Predicting benefit from PARP inhibitors using deep learning on H&E-stained
ovarian cancer slides.
Eur J Cancer. 2024;216:115199. PubMedAbstract available
QUESADA S, Penault-Llorca F, Matias-Guiu X, Banerjee S, et al Homologous recombination deficiency in ovarian cancer: Global expert consensus on
testing and a comparison of companion diagnostics.
Eur J Cancer. 2024;215:115169. PubMedAbstract available
HEMMINGSEN CH, Kjaer SK, Hjorth S, Norby U, et al Maternal use of hormonal contraception and risk of childhood leukemia: A
Scandinavian population-based cohort study.
Eur J Cancer. 2024;215:115168. PubMedAbstract available
November 2024
MATIAS-GUIU X, Lax S, Raspollini MR, Palacios J, et al FIGO 2023 staging for endometrial cancer, when, if it is not now?
Eur J Cancer. 2024;213:115115. PubMedAbstract available
October 2024
WENZEL HHB, Schnack TH, Van der Aa MA, Jensen PT, et al Risk factors for lymph node metastasis in women with FIGO 2018 IA cervical cancer
with a horizontal spread of > 7 mm.
Eur J Cancer. 2024;212:115063. PubMedAbstract available
GIANNOPOULOS S, Naeem S, Nasioudis D, Gossner G, et al Value of surgical lymph node assessment for patients with vulvar melanoma.
Eur J Cancer. 2024;210:114303. PubMedAbstract available
September 2024
BIZZARRI N, Querleu D, Ramirez PT, Dostalek L, et al Survival associated with the use of sentinel lymph node in addition to
lymphadenectomy in early-stage cervical cancer treated with surgery alone: A
sub-analysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study.
Eur J Cancer. 2024;211:114310. PubMedAbstract available
VULSTEKE C, Chambers SK, Perez MJR, Chan JK, et al Tolerability of the niraparib individualized starting dose in the
PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
Eur J Cancer. 2024;208:114157. PubMedAbstract available
August 2024
BOLLINO M, Geppert B, Lonnerfors C, Masback A, et al Prevalence and size of pelvic sentinel lymph node metastases in endometrial
cancer.
Eur J Cancer. 2024;209:114265. PubMedAbstract available
July 2024
FASCHING PA, Hack CC, Nabieva N, Maass N, et al Prognostic impact of selection criteria of current adjuvant endocrine therapy
trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer
patients treated with upfront letrozole.
Eur J Cancer. 2024;209:114239. PubMedAbstract available
SOUTHWORTH E, Thomson JP, Croy I, Churchman M, et al Whole exome sequencing reveals diverse genomic relatedness between paired
concurrent endometrial and ovarian carcinomas.
Eur J Cancer. 2024;208:114205. PubMedAbstract available
May 2024
ROMA C, Esposito Abate R, Sacco A, Califano D, et al Harmonization of homologous recombination deficiency testing in ovarian cancer:
Results from the MITO16A/MaNGO-OV2 trial.
Eur J Cancer. 2024;206:114127. PubMedAbstract available
April 2024
BOLLINO M, Geppert B, Lonnerfors C, Persson J, et al A selective anatomically based lymph node sampling can replace a side specific
pelvic lymphadenectomy in endometrial cancer with failed sentinel node mapping.
Eur J Cancer. 2024;204:114049. PubMedAbstract available
GRAVBROT N, Weil CR, DeCesaris CM, Gaffney DK, et al Corrigendum to "Differentiation of survival outcomes by anatomic involvement and
histology with the revised 2023 International Federation of Gynecology and
Obstetrics staging system for endometrial cancer" Eur. J. Cancer (201) (April)
2024, 113913.
Eur J Cancer. 2024 Apr 2:114017. doi: 10.1016/j.ejca.2024.114017. PubMed
March 2024
TUNINETTI V, Virano E, Salutari V, Ricotti A, et al Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a
nominal use program in Italy: The MITO 44 study.
Eur J Cancer. 2024;203:114039. PubMedAbstract available
BOIDOT R, Blum MGB, Wissler MP, Gottin C, et al Clinical evaluation of a low-coverage whole-genome test for detecting homologous
recombination deficiency in ovarian cancer.
Eur J Cancer. 2024;202:113978. PubMedAbstract available